HIV

News

ViiV's long-acting injectable HIV drug, Cabenuva, has proved to be more effective than daily oral therapy for unsuppressed infections.

News

NICE's decision not to recommend NHS funding of Gilead's twice-yearly injectable for prevention of HIV has drawn fierce criticism from charities.

News

The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least 2 kg.

News

The OpenAI Foundation has committed $100m to help fund a new public health initiative initially focused on hepatitis C.

News

More than 3m people worldwide could be infected with HIV by the end of the decade following a steep fall in international aid funding, says UNAIDS.

News

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.